Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis
详细信息 查看全文
- 作者：Ruo-Xi Wang ; Sheng Chen ; Xi Jin ; Can-Ming Chen…
- 关键词：Breast cancer ; Neoadjuvant chemotherapy ; HER2 ; positive ; Pathological complete response ; Trastuzumab
- 刊名：Breast Cancer Research and Treatment
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：161
- 期：2
- 页码：259-267
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Oncology;
- 出版者：Springer US
- ISSN：1573-7217
- 卷排序：161
文摘
PurposeNeoadjuvant chemotherapy (NCT) plus anti-HER2 agents are the standard of care for locally advanced HER2-positive breast cancer. The aim of this study was to evaluate the prevalence and prognostic impact of HER2 loss in patients with HER2-positive disease treated with neoadjuvant therapy with or without trastuzumab.